Compare British American Tobacco PLC (BTI) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
British American Tobacco PLC vs Novartis AG — how do they compare? British American Tobacco PLC trades at $58.77 (market cap $124.84B), while Novartis AG trades at $149.88 (market cap $288.65B). The key difference: Novartis AG is far larger — about 2.3× British American Tobacco PLC's market cap, and British American Tobacco PLC pays the higher dividend (5.74%). Which is the better fit depends on your goals.
| BTI | NVS | |
|---|---|---|
Market Cap | $124.84B | $288.65B |
Sector | Consumer Staples | Health |
52-Week High | $66.70 | $168.62 |
52-Week Low | $50.39 | $113.50 |
Enterprise Value | $166.06B | $328.67B |
Dividend Yield | 5.74% | 3.15% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
British American Tobacco (BTI) trades at $58.95, down 1.78% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. Fundamentally, the company maintains strong profitability with 30.32% net income margin and attractive valuation at 12.79 P/E ratio. Recent earnings show beats in Q2 and Q4 2025, though Q4 2024 missed expectations. The company is undergoing restructuring with 5,500 job cuts announced in June 2026 to streamline operations and reduce costs.
BTI presents a compelling value opportunity with strong dividend yield and improving earnings trajectory, though facing regulatory headwinds and declining cigarette volumes. The stock's current valuation appears attractive relative to historical levels, supported by robust cash flow generation and strategic pivot toward smoke-free products. Key risks include ongoing regulatory pressures and consumer shift away from traditional tobacco products.
Novartis (NVS) trades at $153.37, down 0.44% today, with a bullish technical signal from moving averages. The company reported $56.67B revenue in 2025 with strong profitability margins (net income margin 23.92%) and recently expanded its oncology pipeline through acquisitions like Myricx Bio. Earnings have been mixed, with a miss in Q1 2026 but a beat in Q4 2025.
Outlook remains stable with revenue projections near $56.6B for 2026, though debt-to-asset ratio has risen to 30.26%. Risks include pipeline execution and competitive pressures. Analysts show cautious optimism with 68% hold ratings, reflecting balanced growth and valuation concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About British American Tobacco PLC
Following the acquisition of Reynolds American, British American Tobacco is neck-and-neck with Philip Morris International to be the largest listed global tobacco company--slightly larger than PMI on net revenue, but slightly smaller on total tobacco volume. British American's Global Drive Brands are Dunhill, Kent, Pall Mall, Lucky Strike, and Rothmans, and it also owns Newport and Camel in the U.S. The firm also sells vapor e-cigarettes, including its Vype brand, heated tobacco, with Glo, as well as roll- your-own and smokeless tobacco products. The company holds 31% of ITC Limited, the leading Indian cigarette-maker.
Read more on BTI →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
